Abstract
Intracellular nucleoside reverse transcriptase inhibitor (NRTI) concentrations are associated with plasma HIV-1 response. Coadministration of protease inhibitors with NRTIs can affect intracellular concentrations due to protease inhibitor inhibition of efflux transporters. Tenofovir-diphosphate (TFV-DP) concentrations within peripheral blood mononuclear cells were compared among individuals receiving either atazanavir or darunavir-based regimens. There was a trend towards higher TFV-DP concentrations among women and among participants receiving atazanavir. TFV-DP intracellular concentrations were positively associated with undetectable plasma HIV-1 RNA.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenine / administration & dosage
-
Adenine / analogs & derivatives*
-
Adenine / pharmacokinetics
-
Adult
-
Anti-HIV Agents / administration & dosage
-
Anti-HIV Agents / pharmacokinetics*
-
Cross-Sectional Studies
-
Cytosol / chemistry*
-
Drug Interactions*
-
Female
-
HIV Infections / drug therapy*
-
HIV Protease Inhibitors / administration & dosage
-
HIV Protease Inhibitors / pharmacokinetics*
-
Humans
-
Leukocytes, Mononuclear / chemistry*
-
Male
-
Middle Aged
-
Organophosphates / administration & dosage
-
Organophosphates / pharmacokinetics*
Substances
-
Anti-HIV Agents
-
HIV Protease Inhibitors
-
Organophosphates
-
tenofovir diphosphate
-
Adenine